We have defined a novel specific target antigen, the receptor tyrosine kinase MuSK, for the auto-antibodies in AChR-Ab–seronegative MG.

Thus, G-protein-coupled receptors can regulate NMDA receptor function indirectly through a PKC-dependent activation of the non-receptor tyrosine kinase (Src) signaling cascade.

Blossomhill Therapeutics Inc. has synthesized new indazole-based macrocyclic compounds acting as ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.